Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 15;61 Suppl 5(Suppl 5):S467-72.
doi: 10.1093/cid/civ499.

Public Health Impact After the Introduction of PsA-TT: The First 4 Years

Fabien V K Diomandé  1 , Mamoudou H Djingarey  2 , Doumagoum M Daugla  3 , Ryan T Novak  1 , Paul A Kristiansen  4 , Jean-Marc Collard  5 , Kadidja Gamougam  3 , Denis Kandolo  2 , Nehemie Mbakuliyemo  2 , Leonard Mayer  1 , James Stuart  6 , Thomas Clark  1 , Carol Tevi-Benissan  7 , William A Perea  8 , Marie-Pierre Preziosi  9 , F Marc LaForce  10 , Dominique Caugant  5 , Nancy Messonnier  1 , Oladapo Walker  2 , Brian Greenwood  6
Affiliations

Public Health Impact After the Introduction of PsA-TT: The First 4 Years

Fabien V K Diomandé et al. Clin Infect Dis. .

Abstract

Background: During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.

Methods: The new vaccine effectiveness evaluation framework was established by the World Health Organization and partners. Meningitis case-based surveillance was strengthened in PsA-TT first-introducer countries, and several evaluation studies were conducted to estimate the vaccination coverage and to measure the impact of vaccine introduction on meningococcal carriage and disease incidence.

Results: PsA-TT implementation achieved high vaccination coverage, and results from studies conducted showed significant decrease of disease incidence as well as significant reduction of oropharyngeal carriage of group A meningococci in vaccinated and unvaccinated individuals, demonstrating the vaccine's ability to generate herd protection and prevent group A epidemics.

Conclusions: Lessons learned from this experience provide useful insights in how to guide and better prepare for future new vaccine introductions in resource-limited settings.

Keywords: Africa meningitis belt; PsA-TT; disease incidence; meningococcal group A; vaccine evaluation framework.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Incidence of meningitis in the African meningitis belt, 2009–2014. Source: www.meningvax.org.
See this image and copyright information in PMC

References

    1. Meningitis Vaccine Project. Vaccine introduction and communication activities. MVP News Digest 2013; 38:1–2.
    1. World Health Organization. Standard operating procedures for enhanced meningitis surveillance in Africa. Geneva, Switzerland: WHO, 2009.
    1. Centers for Disease Control and Prevention. Evaluation of meningitis surveillance before introduction of serogroup A meningococcal conjugate vaccine—Burkina Faso and Mali. MMWR Morb Mortal Wkly Rep 2012; 61:1025–8. - PubMed
    1. Novak RT, Kambou JL, Diomandé FVK et al. . Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012; 12:757–64. - PMC - PubMed
    1. Daugla DM, Gami JP, Gamougam K et al. . Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2013; 383:40–7. - PMC - PubMed